| |
|
|
Session 69
Poster Presentations Antiretroviral Therapy: Predictors and Correlates of Response Thursday 1:30 - 3:30 pm Hall A |
| 572 | Pre-treatment Factors that Predict Responses to Potent Antiretroviral Therapy: Findings from AACTG A5001 C.A. Benson*1, A.C. Collier2, R. Bosch3, K. Bennett3, R. Zackin3, A5001 Protocol Team4 1Univ of Colorado Hlth Sci Ctr, Denver; 2Univ of Washington, Seattle; 3Statistical and Data Analysis Ctr, Harvard Sch of Publ Hlth, Boston, MA; and 4Natl Inst of Hlth /NIAID/DAIDS Adult ACTG, Rockville, MD |
| 573 | Assessing the Relative Efficacy of HAART Regimens Using Early Changes in Plasma Viremia C. Hogan*1,2, M. Louie1,2, S. Vasan1,2, A. Hurley1,2, A. Horowitz1,2, C. Chung1,2, A. Kim1,2, M. DiMascio3, A. Perelson3, D. Ho1,2, M. Markowitz1,2 1Aaron Diamond AIDS Res Ctr, New York, NY; 2Rockefeller Univ, New York, NY; and 3Los Alamos Natl Lab, NM |
| 574 | Viral Dynamics and Their Relationship to Baseline Factors and Week 24 Virological Response in Non-perinatally HIV-1 Infected Adolescents Receiving HAART H. Wu*1, J. Lathey2, S. Spector2, P. Ruan3, J. Lindsey3, M. Hughes3, S. Douglas4, B.J. Rudy5, P.M. Flynn6 1Frontier Sci and Tech Res Fndn, Boston, MA; 2Univ of California at San Diego, La Jolla; 3Harvard Sch of Public Hlth, Boston, MA; 4Children's Hosp of Philadelphia, PA; 5Mt Sinai Med Ctr, New York, NY; and 6St Jude Children's Res Hosp, Memphis, TN |
| 575 | Allelic Variants of MDR1, CYP2C19, and CYP3A5: Distribution and Associations in Patients Receiving Nelfinavir or Efavirenz-containing HAART C. Petersen*1, E. Pun1, S. Myrand2, C. Lin2, J. Paulauskis2, M. Bleavins2, S. Johnson1, E. Daniels 1, R. Haubrich3, 1127 Study Team 1Agouron Pharmaceuticals, Inc, a Pfizer Co, San Diego, CA; 2Pfizer Global RandD, Ann Arbor, MI; and 3Univ of California at San Diego |
| 576 | Evidence of Low-level Viral Replication (< 50 copies/ml) Predicts Eventual Virologic Failure A. L. Pozniak*1, B. G. Gazzard1, M. Yehya1, D. Pillay2, A. Wildfire1, A. Cox1 1Chelsea and Westminster Hosp and Imperial Coll, London, UK and 2Univ of Birmingham and Birmingham Heartlands Hosp, UK |
| 577 | Relationships among Four Measures of Medication Adherence and Virologic Response in ACTG 359 C.V. Fletcher*1, M.A. Testa2, R. Haubrich3, R. Brundage4, H. Jiang2, J. Ickovics5, A. Martinez6, S. Snyder7, R. Gulick8 1Univ of Colorado Hlth Sci Ctr, Denver; 2Harvard Sch of Public Hlth, Boston, MA; 3Univ of California at San Diego; 4Univ of Minnesota, Minneapolis; 5Yale Sch of Med, New Haven, CT; 6Div of Acquired Immunodeficiency Syndrome, Rockville, MD; 7Social and Sci Sys, Silver Spring, MD; and 8Weill Med Coll of Cornell Univ, New York, NY |
| 578 | Cytokine Profiles of Antiretroviral-Naive HIV+ Patients Treated with Lopinavir/Ritonavir (Kaletra)-based Therapy for Three Years A. Landay*1, D. Tokimoto2, M. King2, R. Murphy3, C. Hicks4, J. Eron5, R. Gulick6, M. Glesby6, P. Wolfe7, M. Thompson8, C. White9, C. Benson10, M. Albrecht11, H. Kessler1, S. Brun2 1Rush-Presbyterian-St Luke's Med Ctr, Chicago, IL; 2Abbott Labs, Abbott Park, IL; 3Northwestern Univ, Chicago, IL; 4Duke Univ Med Ctr, Durham, NC; 5Univ of North Carolina, Chapel Hill; 6Chelsea Cornell Clin Trials Unit, New York, NY; 7Pacific Oaks Res, Pacific Oaks, CA; 8AIDS Res Consortium of Atlanta, GA; 9Baylor Coll of Med, Houston, TX; 10Univ of Colorado, Denver; and 11Beth Israel Deaconess Med Ctr, Boston, MA |
| 579 | Analysis of Latent HIV Infection and Sequence Evolution Post Therapy in Semen and Blood Compartments J.K. Craigo*1, B. Patterson2, M. Ding1, R.C. Montelaro1, J. Mellors1, P. Gupta1 1Univ of Pittsburgh, PA and 2Northwestern Univ, Evanston, IL |